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Evidence suggests that compared to younger women, older women are less likely to receive standard management for breast cancer.
Whether this disparity persists once differences in tumour characteristics have been adjusted for has not been investigated in the UK.
A retrospective cohort study involving case note review was undertaken, based on the North Western Cancer Registry database of
women aged X65 years, resident in Greater Manchester with invasive breast cancer registered over a 1-year period (n¼480).
Adjusting for tumour characteristics associated with age by logistic regression analyses, older women were less likely to receive
standard management than younger women for all indicators investigated. Compared to women aged 65–69 years, women aged
X80 years with operable (stage 1–3a) breast cancer have increased odds of not receiving triple assessment (OR¼5.5, 95%
confidence interval (CI): 2.1–14.5), not receiving primary surgery (OR¼43.0, 95% CI: 9.7–191.3), not undergoing axillary node
surgery (OR¼27.6, 95% CI: 5.6–135.9) and not undergoing tests for steroid receptors (OR¼3.0, 95% CI: 1.7–5.5). Women aged
75–79 years have increased odds of not receiving radiotherapy following breast-conserving surgery compared to women aged
65–69 years (OR¼11.0, 95% CI: 2.0–61.6). These results demonstrate that older women in the UK are less likely to receive
standard management for breast cancer, compared to younger women and this disparity cannot be explained by differences in
tumour characteristics.
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The highest incidence of breast cancer in England occurs in
women aged 70 years and older (ONS, 2002). Older women also
experience the worst survival. Women aged 70–79 years have a
76% 5-year relative survival compared to 80% for all ages. For
patients aged X80 years, survival drops considerably to 61%,
beyond what might be expected owing to an increase in age (ONS,
2005). It is important, therefore, to investigate patterns of
management for possible explanations for this.
Compared to younger women, older women with breast cancer
are less likely to be diagnosed via needle biopsy and triple assess-
ment, less likely to undergo primary and axillary node surgery, less
likely to receive radiotherapy following breast-conserving surgery,
and less likely to receive chemotherapy (Busch et al, 1996; He ´rbert-
Croteau et al, 1999; Mandelblatt et al, 2000; Bouchardy et al, 2003;
Gennari et al, 2004; Wyld et al, 2004; Giordano et al, 2005). Such
management of older women is likely to lead to poor local control,
recurrence of the disease and excess mortality (COIN, 1999; BASO,
2005; SIGN, 2005).
The extent to which tumour characteristics can explain
difference in management is of primary importance. Older women
could legitimately receive different treatment to younger women
owing to, for example, larger tumour size or differences in receptor
status (COIN, 1999; SIGN, 2005). Although tumour characteristics
provide a basis for treatment decisions in published guidelines,
how tumour characteristics vary with age remains uncertain (Fisher
et al, 1997; Diab et al, 2000). There is evidence that time between
onset of symptoms of breast cancer and first hospital visit is
greater for older patients and that variation in some tumour
characteristics by age, such as stage and tumour size, is related to
that delay (Ramirez et al, 1999; Richards et al, 1999). However,
regardless of why tumour characteristics differ between age groups,
once older women present with breast cancer they are less
likely to receive standard management. It is important, therefore,
to establish the extent to which tumour characteristics account
for this in epidemiological, multivariate studies, which adjust
for the possible confounding effects of variation in tumour
characteristics.
Studies undertaken so far in the UK have been limited to uni-
variate investigation of the relationship between age and treat-
ment. Two studies based in England found that older women with
early stage breast cancer were less likely to receive radiotherapy
following breast-conserving surgery, axillary node surgery and
chemotherapy and more likely to receive hormone therapy as their
sole form of treatment (Golledge et al, 2000; Wyld et al, 2004). An
audit of symptomatically presenting breast cancer patients also
identified considerable difference in several aspects of manage-
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sment between younger and older women (Monypenny, 2004).
However, none of these UK studies adjusts for the possible
confounding effects of differences in tumour characteristics on
treatment choice in multivariate models. Therefore the extent to
which tumour characteristics account for under treatment of older
women with breast cancer in the UK, has not been established.
The evidence from such studies conducted in North American
(He ´rbert-Croteau et al, 1999; Mandelblatt et al, 2000; Du and
Goodwin, 2001; Yancik et al, 2001; DeMichele et al, 2003; Giordano
et al, 2005) and to a lesser extent mainland Europe (Bouchardy
et al, 2003; Nagel et al, 2003; Gennari et al, 2004) suggests that age
predicts non-standard management when tumour characteristics
are accounted for. However, no similar studies have been
undertaken in the UK and these results may not be representative
of practice in the UK, especially in light of the comparatively lower
survival rate of women aged X65 years compared to the rest of
Europe (Vercelli et al, 2000) and the United States (ONS, 2002; Ries
et al, 2003) and differences in health care services between
countries.
In addition, previous studies have not investigated variation in
receipt of steroid receptor testing by age group amongst older
women with breast cancer. As the results of this test determines
suitability for hormone therapy and reliance on this method of
treatment alone rises with increasing age group (Wyld et al, 2004),
it is important to establish if testing varies with age.
This study, therefore, investigates whether age predicts a range
of indicators of standard management, including receptor testing,
amongst a population of women, registered with invasive breast
cancer, aged X65years and resident in Greater Manchester (UK)
accounting for tumour characteristics using logistic regression
analysis.
MATERIALS AND METHODS
Minimal standards of acceptable management for non-metastatic
breast cancer were developed based on published guidelines
(BASO, 1998; SIGN, 1998; COIN, 1999; NWBG, 1999) in consulta-
tion with two consultant breast surgeons, a medical and a clinical
oncologist and an epidemiologist. ‘Operable breast cancer’ is
defined as presenting with UICC stage 1–3a assessed on the basis
of diagnostic procedures undertaken before therapeutic surgery
(SIGN, 1998; NWBG, 1999) (see Box 1).
Pretreatment assessments of tumour characteristics, tumour size
and stage were recorded based on clinical and imaging assess-
ments (cTNM). Overall assessments of these tumour character-
istics were based on postsurgery pathological assessment (pTNM),
if undertaken and pretreatment assessment if not (UICC, 1997).
To test the null hypothesis that older women are as likely to
receive these standards of management, whilst accounting for
tumour characteristics, we undertook an observational retro-
spective cohort study. Our sample included all women aged X65
years old, resident in Greater Manchester, with Cancer Registry
anniversary dates for invasive breast cancer during 1999 (see
Box 2).
Case note reviews were undertaken in order to check and
supplement Cancer Registry information on management, tumour
variables and age. All cases were followed to 31 December 2001. A
proforma to collect information from case notes was developed
and checked for inter-observer and test–retest reliability using
Cohen’s k statistic in 3% of cases reviewed, chosen at random. In
addition, quality checks of approximately 10% of the database
entries against the original proformas were undertaken.
Univariate analysis of categorical variables used the Pearson’s w
2
test and the w
2 test for trend. All tests are two-tailed with a¼0.05
unless otherwise specified.
Significant indicators of standard management associated with
age in univariate analysis are used as independent variables in the
subsequent logistic regression (non-stepwise). All logistic regres-
sion models meet the recommendation of at least 10 cases per
variable (Norman and Streiner, 2000). In practice, there were no
problems with convergence of the maximum likelihood estimates
(Tabachnick and Fidell, 2001). To meet this recommendation
the following strategy was used to select explanatory variables. All
logistic regression models include the variables of age group,
hospital type (university vs district) and deprivation (Townsend
index quintiles 1–2 vs 3–5). Tumour characteristics selected for
entry into the logistic regression models had to be significantly
associated with age in the univariate analysis, known to the
clinician at the time the management decision was made, have
sufficient number of cases with data and not be highly associated
with each other.
Data were analysed using SPSS 11.5 for Windows; 95% confi-
dence intervals for percentages were estimated using the CIA
(confidence interval analysis) Programme version 1.2 (Gardner
et al, 1992).
RESULTS
Selection bias
Data from the Cancer Registry revealed that the age group of
patients whose notes were not reviewed (n¼136) did not differ
Box 1 Minimal standards of management for non-metastatic invasive
breast cancer
Triple assessment
All operable* invasive breast carcinomas are diagnosed via clinical assessment,
imaging and fine needle aspiration or core biopsy. All three tests need to take
place within 1 month.
Surgery
Surgery should be undertaken, within 3 months of initial diagnosis, for all cases
of operable* breast cancer.
Axillary node surgery
Operable* cases undergoing surgery should have some form of axillary node
dissection.
Radiotherapy following breast conserving surgery
All patient undergoing breast conserving surgery, and not going on to have a
mastectomy, should receive radiotherapy within 6 months of their last breast
conserving surgery.
Receptor testing:
All patients should have a steroid receptor test, within 4 months of initial
diagnosis, to assess their suitability for hormone therapy.
*‘Operable breast cancer’ ¼UICC stage 1–3a at presentation on basis of
diagnostic procedures before therapeutic surgery undertaken (cTNM)(UICC, 1997;
SIGN, 1998)
Box 2 Selection of sample
Study sample (n¼729) All women aged X65 years, resident in Greater
Manchester, recorded on Cancer Registry with an
anniversary date for invasive breast cancer in 1999.
Exclusions (n¼249) Case notes not available for review (n¼136); pilot
study – randomly selected (n¼33); metastatic
breast cancer diagnosed at presentation (n¼51);
Diagnosis and/or hormone therapy pre 7 July 1998
(n¼21); Anniversary date pre 1 January 1999
(n¼2); Ductal carcinoma in situ (n¼4); Moved
into/away from Greater Manchester during
treatment (n¼2).
Final sample n¼480
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ssignificantly from that of the study sample (n¼480) (Trend
w
2¼3.04; df¼1; P¼0.081). However, cases not reviewed were
less likely to have surgery (Pearson’s w
2¼26.54; df¼1; Po0.001),
indicating that the study sample over represents those receiving
surgery. Nonetheless, older women are significantly less likely to
receive surgery for both cases not reviewed (Trend w
2¼17.59;
df¼1; Po0.001) and the study sample (Trend w
2¼97.54; df¼1;
Po0.001), demonstrating that the pattern of decreasing surgery
with increasing age would still have been found if the complete
study sample of all registered patients had been achieved.
Reliability
Inter- and intra-rater agreement levels of the proformas all
satisfied k 40.6, indicating substantial to perfect agreement levels
(Landis and Koch, 1977).
Overall proportions receiving non-standard management
Substantial proportions of all patients in the study failed to receive
standard management with the proportions not receiving standard
management ranging between 19% for triple assessment to 41% for
steroid receptor testing (Table 1).
Of the 169 patients who did not undergo steroid receptor testing,
75% (127) were still treated with tamoxifen, 44% (74) did not
undergo surgery and for 32% (54) tamoxifen was their sole form
of treatment (i.e. no surgery, radiotherapy or chemotherapy).
Of the 243 patients who did undergo steroid receptor testing,
15% (36) were found to be negative for both oestrogen (ER) and
progesterone (PR) receptors. Thirty-five of these patients were
still treated with hormone therapy. However, all 36 patients also
received some other form of treatment with 32 undergoing
surgery.
Univariate analysis
The results of the univariate analysis are presented in Figure 1. The
proportions of women not receiving standard management
increased with age for all indicators of standard management.
The difference in standard management between age groups was
significant for all indicators of standard management, as were the
tests of trend (Po0.001). Even when presenting with operable
breast cancer, older women are less likely to be diagnosed by triple
assessment, less likely to undergo any surgery within 3 months of
diagnosis, less likely to have axillary node dissection as part of this
surgery and less likely to have any treatment other than hormone
therapy. In addition, older women are less likely to undergo a
steroid receptor test within 4 months of diagnosis and less likely to
have radiotherapy following breast-conserving surgery.
Multivariate analysis
The results of the multivariate analysis are given in Table 2.
Patients aged X80 years with operable breast cancer have more
than five times the odds of not receiving triple assessment for
operable breast cancer, compared to the reference group of 65–69
year olds, controlling for pretreatment assessment of tumour size
(mm) (OR¼5.5 95% CI: 2.1–14.5). Patients aged 70–74 and
75–79 have 7.9 (95% CI: 1.4–44.4) and 11.0 (95% CI: 2.0–61.6)
times the odds, respectively, of not undergoing radiotherapy
following breast-conserving surgery as compared to 65–69 year
olds, controlling for tumour grade (I, II or III) and overall tumour
stage. Patients aged X80 years were found to have 3.0 (95% CI:
1.7–5.5) times the odds of not receiving a steroid receptor test
within 4 months of diagnosis compared to 65–69 year olds,
controlling for overall tumour stage.
Patients aged 70–74 have 6.7 (95% CI: 1.4–32.6) and patients
aged X80 years have 43.0 (95% CI: 9.7–191.3) times the odds of
not receiving surgery for operable breast cancer compared to 65–
69 year olds. All age groups X70 years have significantly increased
odds of not receiving axillary node surgery. These odds increase
with age up to patients aged X80 years who have 27.6 (95% CI:
5.6–135.9) times the odds of not having axillary node surgery
compared with 65–69 year olds. These logistic regressions account
for pretreatment stage.
Tumour characteristics were found to be predictive of not
receiving standard management. Patients with pretreatment stage
2 tumours are less likely to receive surgery compared to patients
with stage 1 tumours (OR¼2.8 95% CI: 1.3–6.0) and the odds of
not receiving triple assessment increase by 1.02 per mm increase in
pretreatment tumour size (95% CI: 1.00–1.04).
Hospital type was predictive of not undergoing triple assessment
and not receiving surgery for operable cancers. District hospitals
performed less well than university hospitals (triple assessment
OR¼4.5 95% CI: 2.0–9.9; surgery OR¼2.2 95% CI: 1.0–4.5).
DISCUSSION
We present evidence that, even when differences in the nature of
the disease (as measured by tumour characteristics associated with
age) are accounted for, older women in Greater Manchester are
less likely to receive standard management for breast cancer
compared to younger women. Furthermore, there were age trends
in our data with the oldest women fairing least well. Compared
with her 65–69-year-old counterpart, the odds of a women aged 80
or older not receiving triple assessment for operable breast cancer
are five and a half times higher, and the odds of her not receiving
surgery are more than 40 times higher, controlling for social
deprivation, hospital type as well as size and grade of tumour
respectively.
For triple assessment, primary surgery and steroid receptor
testing, there appears to be a threshold effect, with women aged
o 80 years being treated similarly, but X80 years not receiving
timely diagnostic testing and being treated by hormone therapy
alone. For axillary surgery and radiotherapy the pattern is more
linear, as age increases the odds of standard treatment decreases.
The results of this study are in broad agreement with previous
studies from North America (He ´rbert-Croteau et al, 1999;
Mandelblatt et al, 2000; Giordano et al, 2005) and mainland
Europe (Bouchardy et al, 2003; Nagel et al, 2003; Gennari et al,
2004) as they demonstrate an increase in non-standard manage-
ment once tumour characteristics are accounted for. The two
UK studies, described earlier, demonstrated similar age related
Table 1 Proportion of all patients in the study not receiving standard management for each indicator
Indicator of standard management (baseline number) % (n) not receiving standard management 95% confidence interval
Triple assessment (n¼305) 19.0 (58) 14.6–23.4
Surgery (n¼305) 22.0 (67) 17.3–26.6
Axillary node surgery (n¼236) 16.9 (40) 12.2–21.7
Radiotherapy following breast conserving surgery (n¼130) 40.8 (53) 32.3–49.2
Steroid testing (n¼412) 41.0 (169) 36.3–45.8
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confounding effects of variation in tumour characteristics on
management were not adjusted for in multivariate analysis. This
study builds on previous work by demonstrating that even when
tumour characteristics are accounted for increasing age predicts
non-standard management of postmenopausal women in a UK
based population.
In addition, unlike previous studies, patterns of steroid receptor
testing by age group were investigated. The percentage not
receiving a receptor test varied the least between age groups
compared to the other indicators of standard management with
30% of the youngest women (65–69 years) compared to 41% of
all age groups in this study not undergoing receptor testing. The
overall percentage not receiving receptor testing seems high, as
steroid receptor testing was recommended in guidelines in use in
clinics at the time of the study (BASO, 1998; SIGN, 1998; COIN,
1999; NWBG, 1999), and suggests that further studies including
women o65years old are needed to establish what proportions of
younger women undergo receptor testing. Audit data for screen
detected breast cancers in 2000/1 do however suggest that, among
the screened population (predominantly aged 50–64 year olds),
only 12% of women with invasive breast cancer in the UK and
6% in Greater Manchester did not undergo steroid testing for
ER receptors (Lawrence and George, 2001).
Nevertheless, failure to investigate receptor status among
patients in this study resulted in treatment decisions being made
without fundamental information. As 75% of patients not receiving
a steroid receptor test were still treated with tamoxifen they were
prescribed a treatment without this evidence that it would work
and for 32% of these patients it was the only therapy they received.
Moreover, all but one of the 36 patients, who were found to be
negative for both ER and PR receptors, were still treated inappro-
priately with tamoxifen. Given the toxicity of tamoxifen in this age
group regarding increased risks of thromboembolic events and
endometrial cancer (Fisher et al, 2005), this practice is potentially
dangerous. However, all 36 patients received some other form of
treatment and for 32 patients this was surgery. This suggests that
although receptor testing does not deter inappropriate hormonal
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Figure 1 Percentage (n) of breast cancer patients not receiving standard management by age group. (A) No triple assessment for operable breast cancer
(n¼305). (B) No surgery for operable breast cancer (n¼305). (C) No axillary node surgery for operable breast cancer (n¼236). (D) No radiotherapy
following breast-conserving surgery for non-metastatic breast cancer (n¼130). (E) No steroid receptor test for non-metastatic breast cancer (n¼419).
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sTable 2 Odds ratios (95%CI) of not receiving standard of management from logistic regression models accounting for tumour characteristics
95% CI for odds ratio
Variables P-value Odds ratio Lower Upper
Standard of management: Triple Assessment (n¼305) Not receiving triple assessment (vs receiving triple assessment) for operable breast cancer
Pretreatment tumour size (mm) 0.032 1.02 1.00 1.04
Type of hospital University 1.00
District o0.001 4.46 2.00 9.94
Townsend index (quintiles) 1–2 1.00
3–5 0.971 1.01 0.53 1.92
Age group (years) Overall 0.002
65–69 (reference) 1.00
70–74 0.092 2.52 0.86 7.40
75–79 0.187 2.01 0.71 5.64
80+ 0.001 5.49 2.08 14.45
Standard of management: Surgery (n¼305) Not receiving surgery (vs receiving surgery) for operable breast cancer
Pretreatment stage (UICC) Overall 0.027
1 1.00
2 0.008 2.81 1.31 6.04
3a 0.195 3.20 0.55 18.63
Type of hospital University 1.00
District 0.042 2.15 1.03 4.48
Townsend Index (quintiles) 1–2 1.00
3–5 0.864 0.94 0.46 1.93
Age group (years) Overall o0.001
65–69 (reference) 1.00
70–74 0.018 6.73 1.39 32.58
75–79 0.060 4.46 0.94 21.19
80+ o0.001 43.03 9.68 191.25
Standard of management: Axillary node surgery (n¼236) Not receiving axillary node surgery (vs receiving axillary node surgery) for operable breast cancer
Pretreatment stage (UICC) Overall 0.877
1 1.00
2 0.852 0.93 0.43 2.01
3a 0.613 0.54 0.05 5.91
Type of hospital University 1.00
District 0.050 2.27 1.00 5.17
Townsend index (quintiles) 1–2 1.00
3–5 0.431 0.72 0.31 1.64
Age group (years) Overall o0.001
65–69(reference) 1.00
70–74 0.012 7.85 1.56 39.36
75–79 0.002 11.76 2.54 54.50
80+ o0.001 27.59 5.60 135.87
Standard of management: Radiotherapy (n¼130) Not receiving radiotherapy within 6 months of breast conserving surgery (vs receiving radiotherapy)
Overall tumour stage 1 1.00
2–3 0.444 0.65 0.21 1.98
Tumour grade Overall 0.306
I 1.00
II 0.148 0.37 0.10 1.42
III 0.751 0.79 0.18 3.49
Type of hospital University 1.00
District 0.630 1.32 0.42 4.13
Townsend index (quintiles) 1–2 1.00
3–5 0.218 2.48 0.58 10.54
Age group (years) Overall o0.001
65–69 (reference) 1.00
70–74 0.019 7.89 1.40 44.43
75–79 0.007 10.97 1.95 61.59
80+ o0.001 406.48 26.07 6337.48
Standard of management: Receptor testing (n¼412) Not receiving a steroid receptor test within 4 months of diagnosis (vs receiving a receptor test within 4 months)
Overall tumour stage 1 1.00
2–3 0.709 1.09 0.69 1.71
Type of hospital University 1.00
District 0.076 1.52 0.96 2.42
Townsend index (quintiles) 1–2 1.00
3–5 0.150 0.71 0.45 1.13
Age group (years) Overall 0.001
65–69(reference) 1.00
70–74 0.167 1.54 0.83 2.85
75–79 0.906 1.04 0.56 1.90
80+ o0.001 3.02 1.66 5.52
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streatments it does discourage reliance on treatment by hormone
therapy alone.
Limitations of this study include potential selection bias,
restriction of the sample to one geographical region and patient
preferences and health status not being taken into account.
Selection bias, owing to the proportion of cases not reviewed,
may limit the generalisability of the results of this study. How-
ever, a high proportion (593 of the 729 registered cases) were
reviewed (81%). Moreover, a selection bias analysis indicates that
the age range in the sample is similar to the population and that,
although the sample overestimates the proportion received
surgery, a similar pattern of decreasing standard management
with age would have been found, if the complete sample was
achieved.
This study included only one region of England. The extent to
which we can generalise these results nationally may therefore be
limited especially as geographical variations in survival rates, as
well as access to diagnostic and treatment services for cancer have
been identified in England (NAO, 2004). However, as the variation
in survival by Strategic Health Authority is less for breast cancer
than other major cancers, these results may be more applicable
nationally than regional studies of other cancers.
Patient preferences were not accounted for in this study and
may explain some of the difference in treatment between younger
and older women. Yellen et al (1994) found that older patients
were as likely as their younger counterparts to agree to aggressive
therapy such as chemotherapy following surgery. Conversely,
other researchers have reported that older women with breast
cancer are more likely than younger women not to want further
therapies after surgery (Newcomb and Carbone, 1993; Mandelblatt
et al, 2000). Mandelblatt et al (2000), however, still found that age
predicted non-receipt of radiotherapy following breast-conserving
surgery, even when these patient preferences were accounted for.
Clearly, more UK-based research is needed to investigate the
influence of patient preference on the disparity in management
identified in this study. However, although patient preferences
may play a part in treatment decisions for surgery and radio-
therapy, patient choice is less likely to be an influence in diagnostic
services such as triple assessment and the decision to send a
specimen for receptor testing rests with the clinician. Without
knowledge of steroid receptor status it is not possible for the
clinician or the patient to make an informed decision on choice of
treatment.
The difference in management between older and younger
women with breast cancer may also be related to the patients’
fitness for treatment. This has been cited in the guidelines as a
legitimate reason for non-standard management of older women
(SIGN, 1998; NWBG, 1999). Several studies provide evidence that
this disparity in treatment still occurs when comorbidity is
accounted for (He ´rbert-Croteau et al, 1999; Du and Goodwin,
2001; Yancik et al, 2001; DeMichele et al, 2003; Nagel et al, 2003;
Gennari et al, 2004; Giordano et al, 2005). However, few control for
any further measures of general health (Silliman et al, 1997;
Mandelblatt et al, 2000; Hurria et al, 2003). Moreover, no similar
studies from the UK have been reported to date. Further studies,
accounting for wider measures of health as well as comorbidity
and tumour characteristics, based on a UK sample of breast cancer
patients are needed.
Despite these limitations, our results reinforce and add weight to
the body of literature identifying the disparity in the treatment of
older and younger women with breast cancer. The strengths of this
study include the use of a registry-based population of all breast
cancer patients, measurement of a range of indicators of standard
management and incorporation of the possible confounding effects
of systematically selected tumour characteristics as well as social
deprivation and hospital type in a logistic regression analysis. To
the best of our knowledge this is the only UK-based study to do
this. We found that older women do not receive the same
management as younger women and that this is owing to their age
rather than differences in tumour status.
Despite this, in a survey of UK breast surgeons, 75% reported
that they would treat older breast cancer patients in a similar way
to younger breast cancer patients and 98% responded that the
cutoff point for primary surgery was ‘not age related’ (Audisio
et al, 2004). Clearly there is an apparent difference in clinicians’
perceptions of how older breast cancer patients are treated and
actual practice.
Standard management of breast cancer was infrequent in older
women in Greater Manchester. The lack of diagnostic and steroid
receptor testing resulted in older cancer patients having no
effective treatment with 41% not undergoing a steroid receptor
test, 32% of whom received tamoxifen as their sole form of
treatment. Mortality of elderly breast cancer patients is unlikely to
improve where this pattern of management persists.
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